Cognitive decline profiles associated with lewy pathology in the context of Alzheimer’s disease neuropathologic change by Jon B. Toledo, David P. Salmon, Melissa J. Armstrong, Douglas Galasko

Get full text

Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease by Douglas Galasko, Meifang Xiao, Desheng Xu, Denis Smirnov, David P. Salmon, Nele Dewit, Jeroen Vanbrabant, Dirk Jacobs, Hugo Vanderstichele, Eugeen Vanmechelen, Alzheimer's Disease Neuroimaging Initiative (ADNI), Paul Worley

Get full text

Prognostic value of plasma biomarkers for informing clinical trial design in mild-to-moderate Alzheimer’s disease by Yuqi Qiu, Diane M. Jacobs, Karen Messer, David P. Salmon, Cheryl L. Wellington, Sophie Stukas, Carolyn Revta, James B. Brewer, Gabriel C. Léger, Brianna Askew, Lia Donahue, Stephen Kaplita, Vladimir Coric, Irfan A. Qureshi, Howard H. Feldman, The Alzheimer’s Disease Cooperative Study T2 Protect AD Study Group

Get full text

Protocol for a seamless phase 2A-phase 2B randomized double-blind placebo-controlled trial to evaluate the safety and efficacy of benfotiamine in patients with early Alzheimer's di... by Howard H Feldman, José A Luchsinger, Gabriel C Léger, Curtis Taylor, Diane M Jacobs, David P Salmon, Steven D Edland, Karen Messer, Carolyn Revta, Sarah A Flowers, Kerry S Jones, Albert Koulman, Kevin E Yarasheski, Philip B Verghese, Venky Venkatesh, Henrik Zetterberg, January Durant, Jody-Lynn Lupo, Gary E Gibson, ADCS BenfoTeam Study Group

Get full text